Background: To assess public health relevance of targets on tobacco smoking, information is needed on the decline in future mortality following smoking cessation. WHO's Health for All (HFA) and other targets on tobacco smoking in the European Union (EU) were therefore simulated. Methods: A computer simulation model, Markov multi-state type, was developed using published age-and sex-specific information on population sizes, smoking prevalences, total and cause-specific mortality rates and corresponding relative risks for ex-and current smokers. The probabilities to start and quit smoking (transition rates) were estimated. Targets on smoking cessation included WHO's HFA target (country-specific smoking prevalence is reduced to 20% by 2015), and a theoretical maximum target (all smokers quit instantly). Simulation of these targets was based on changes in transition rates for smoking behaviour. For each target, the cumulated number of all-cause and cause-specific deaths between 1994 and 2015 was estimated for each EU member state. Then, the absolute and relative reduction in the number of deaths compared to a reference scenario, in which transition rates for smoking behaviour remained constant, were estimated for the EU as a whole. Results: WHO's HFA target was expected to give a total mortality reduction by 2015 of 2.5% (around 1.1 million deaths) among men and 0.8% (almost 350,000 deaths) among women in the EU. Overall, the expected mortality declines in the HFA target were about 40-50% (men) and 30% (women) of the expected declines in the maximum target. The largest impact of the HFA target would be reached for lung cancer mortality. Conclusions: These results emphasize the need for policymakers in each EU member state to put strong effort into encouraging smokers to quit smoking.
It is well known that cigarette smoking is the number one preventable risk factor for mortality in the European Union (EU). Established smoking-related causes of death include several forms of cancer, cardiovascular diseases and chronic obstructive pulmonary disease (COPD).
1,2 Peto et al. 3 estimated that 15% of all deaths in 1995 in the EU could be attributed to cigarette smoking. A reduction in smoking prevalence may thus be of great importance in the efforts to reduce future mortality in the EU.
In the Health for All (HFA) policy document, the World Health Organization has formulated several targets for future health policy in the European Union. 4 One of these targets implies a reduction in future prevalence of cigarette smoking, to a maximum of 20% by the year 2015. To assess the public health relevance of such smoking-cessation-based targets, one should have information on the estimated decline in future mortality following such a reduction in smoking prevalence. We therefore simulated this HFA target and other smoking-cessation-based targets by means of a computer simulation model, and estimated the future reduction in the number of deaths from cancer, cardiovascular diseases and COPD and the number of deaths from all causes through smoking cessation in the European Union.
METHODS

Simulation model
We used a mathematical computer simulation model to estimate the reduction following smoking cessation in the number of deaths from all causes and in the number of deaths from smoking-related cancer (lung, oral cavity and pharynx, larynx, oesophagus, pancreas, bladder and kidney), coronary heart disease (CHD), stroke and chronic obstructive pulmonary disease (COPD) in the European Union. Our model was based on the Markov multi-state model, using transition rates to indicate the probability of subjects moving from one state to another, for example the probability of dying or the probability of starting or quitting smoking.
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At the beginning of the simulation (1994), the model's population in each of the 15 EU member states consisted of male and female never, ex-and current smokers, in 1-year age classes starting from age 15 up to age 85 and over, each with specific probabilities of starting and quitting smoking and specific total and cause-specific mortality rates (transition rates). Several smoking-cessation-based targets were formulated, each with target-specific transition rates for smoking behaviour during successive years of the simulation period, which led from 1994 up to 2015. In 1994, for each target, the number of subjects in each state of smoking behaviour, i.e. the number of never, exand current smokers, was estimated using published data on population sizes and on the prevalence of ex-and current smokers. In subsequent years of the simulation, the number of 15-year-old never, ex-and current smokers, who can be considered as 'new' members of our population, were estimated similarly. For the remaining age classes, the number of never, exand current smokers in each age class in a subsequent simulation year depended on the numbers in each smoking stratum of the preceding year, the target-specific transition rates for smoking behaviour, and the total mortality rates. The yearly number of future deaths from all causes and from each smoking-related disease was estimated for each target, using the target-specific number of never, ex-and current smokers and the total and cause-specific mortality rates among the separate smoking categories.
Input data
The population sizes for men and women in each EU member state in 1994 were derived from the United Nations (table 1) .
From these data, which are given in 5-year age classes, the population sizes were estimated for each 1-year age class in 1994 (S-Plus 2000, Professional Release 2. MathSoft Inc., Seattle, 2000) . For the subsequent years of the population , the population sizes of the 15-year-olds, the youngest age class in the population, were estimated by the same method, except that the UN population sizes were population size projections. The population size of all other age classes in the subsequent simulation years depended on the estimated number of never, ex-and current smokers. Age-and sex-specific prevalences of ex-and current cigarette smoking (manufactured and hand-rolled) in the EU member states were derived from ten Eurobarometer surveys carried out from 1987 to 1995 (numbers 27, 29, 30, 31, 32, 34.1, 36, 38, 41 and 43) (table 1) . 7 In each survey, a random sample was drawn from the population aged 15 years and over in each country. For each country, approximately 1000 subjects were interviewed in their homes, except for the United Kingdom (1000 in Great Britain and 300 in Northern Ireland), Germany (1000 in both former West and East Germany), and in survey No. 32 (1989) (twice as many subjects in each country). Since 1990, Germany includes East Germany. Data were weighted by sex, age, region and size of locality to obtain representative data for the whole country. For each country, the weighted age-and sex-specific prevalence were averaged over the ten Eurobarometer surveys. For both men and women, ex-and current smoking prevalences were then smoothed over 1-year age categories (S-Plus 2000) . These data were assumed to be the smoking prevalence at the beginning of the simulation (1994) . From these prevalences of smoking behaviour, the age-and sex-specific transition rates for smoking behaviour were estimated, i.e. the probability to move from one state of smoking behaviour to another during one year (Mathematica Version 4. 1. Wolfram Research, Champaign, USA, 2000) . These transition rates included the start rate, which is the probability of a never smoker becoming a smoker within 1 year, and the stop rate, which is the probability of a smoker quitting smoking within 1 year. The stop rate is the net rate, incorporating the rate of quitting and relapse after quitting. Because sufficient time series of past smoking prevalences were not available, it was assumed that the transition rates for smoking behaviour had not changed over time.
Information on the national age-and sex-specific mortality rates for total mortality and for smoking-related cancer, CHD, stroke and COPD in each member state of the EU was obtained from the World Health Organization (WHO) Databank, in 5-year age classes. The mortality rates were smoothed over 1-year age classes (S-Plus 2000) . In each member state, these data were collected in 1994 (table 2a and 2b). Since mortality rates among never, exand current smokers separately were not available from published databases, these rates were estimated for each member state using the prevalences of smoking behaviour, the total and cause-specific mortality rates in the total population, and the relative risks of ex-and current smokers. It was assumed that the age-specific mortality rates in each category of smoking behaviour were constant over time.
The relative risks of ex-and current smokers for total mortality and for mortality from smoking-related diseases were taken from the Cancer Prevention Study II (CPS II) ( Targets A 'reference scenario' was formulated in which the transition rates for smoking behaviour at the beginning of the simulation remained unchanged in subsequent years. Several alternative targets were formulated based on two approaches: a reduction of the prevalence of smokers in each EU member state to a fixed percentage and a reduction of the prevalence of smokers by a fixed percentage. These reductions were achieved by varying the age-and sex-specific start and/or stop rates. In the 'HFA target' and the theoretical 'maximum target', a reduction of the smoking prevalence to a fixed percentage was simulated. The HFA target was based on the Health for All (HFA) target of the World Health Organization with respect to tobacco smoking, which implies that the prevalence of nonsmoking should be at least 80% in each country of the EU by the year 2015. 4 In the HFA target, a reduction of the percentage of smokers (male and female) to 20% in each country by the year 2015 was simulated. This was achieved by increasing the ageand sex-specific stop rate with the same proportion for each age class and simulation year. Since the percentage of smokers was already around 20% among men in Sweden and among women in Portugal, in these cases the stop rate was not changed. In the maximum target, it was simulated that in each country no individual would start smoking and that all smokers would quit instantly, i.e. a reduction of the smoking prevalence to 0% by the year 1995, achieved by assuming the start rate to be 0 and the stop rate to be 1 for each age class and simulation year, from 1995 onwards. Using this target, the theoretical maximum reduction in mortality following smoking cessation can be estimated. For each EU member state, reductions in the smoking prevalence by a fixed percentage were then simulated. In 20 consequent simulations, the smoking prevalence was reduced in steps of 5%: from a 0% reduction to a 100% reduction, relative to the smoking prevalence in 1994, achieved by the year 2015. Also in these targets, the age-and sex-specific stop rate was increased in the same proportion for all age classes and successive simulation years, from 1995 onwards.
Model outcome variables
The yearly number of deaths in each country were cumulated over time to obtain the total number of deaths from each 
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smoking-related disease and from all causes between 1994 and 2015, among men and women aged 15 years and over. For each alternative target, the absolute and relative reduction in mortality compared to the reference scenario was computed. For each target, the number of deaths from each cause in the European Union as a whole was estimated by cumulating the number of deaths in all 15 member states in the European Union.
In the estimations, the number of deaths from smoking-related cancer, other than lung cancer, were presented as one group, 'other cancers'. Table 4 reflects the country-specific cumulated number of deaths from lung cancer, other smoking-related cancers, CHD, stroke, COPD and all causes that was expected in the reference scenario, among men and women, over the period 1994-2015. In all countries, cardiovascular diseases, especially coronary heart disease (CHD), were the number one cause of death. In general, the lowest number of deaths was expected for COPD among men and for lung cancer among women. The most important types of cancer within the group of 'other cancers' were bladder cancer and pancreatic cancer among men and pancreatic cancer among women (data not shown).
RESULTS
In the HFA target, the largest effect of smoking cessation would be reached for lung cancer mortality. Lung cancer mortality would decrease by around 11% among men and 8% among women, accounting for a reduction of about 372,000 and 78,000 male and female lung cancer deaths respectively over the simulation period ( figure 1 ). Among men, the group of 'other cancers' would be reduced by 6.4%, stroke by 2.1%, CHD by 1.3% and total mortality by 2.5% (around 1.1 million deaths), from 1994 up to 2015. Due to the decrease in total mortality, which results in a higher number of people at risk, mortality from COPD would increase among men by 0.8% (16,000 deaths). Among women, mortality from COPD would decrease by 2.0% (24,000 deaths) in the HFA target ( figure 1) . Overall, the expected decline in mortality after smoking cessation was lower among women than among men, due to the lower smoking prevalence among women ( figure 1) . Although the expected absolute reduction in 'other cancers' (25,500 deaths) was lower than that in stroke (37,500 deaths) and similar to that in CHD (24,000 deaths) among women, the expected relative reduction was higher (2.1% for 'other cancers' compared to 0.6% and 0.3% for stroke and CHD respectively). Total mortality would be reduced by 0.8% (almost 350,000 deaths) from 1994 to 2015 in the HFA target. Obviously, the expected effect of the theoretical maximum target on mortality was larger than that of the HFA target, but 6 1,197.8 6,904.0 6,513.7 1,185.8 45,877.4 EUROPEAN JOURNAL OF PUBLIC HEALTH VOL. 14 2004 NO. 1 the relative position of the causes of death in the expected decline in number of deaths was similar (data not shown). If all smokers would quit smoking instantly, the cumulated lung cancer mortality from 1994 to 2015, among men and women respectively, would be reduced by 28% and 29%, 'other cancers' by 16% and 7.4%, stroke by 4.3% and 1.7%, CHD by 2.9% and 0.8% and total mortality by 6.3% and 2.6%. As for the HFA target, an increase in COPD was expected among men (3.8%) and a decrease in COPD was expected among women (6.3%) (data not shown).
The reduction in the number of deaths by reducing the smoking prevalence in each EU member state by a fixed percentage, in 20 steps of 5% from a 0% reduction to a 100% reduction relative to the smoking percentage in 1994, achieved by the year 2015 was then estimated ( figure 2a and 2b) . For instance, a relative reduction in smoking prevalence of 35% between 1994 and 2015 in each EU member state (for example from a smoking prevalence of 40% in 1994 to 26% in 2015) would reduce the expected lung cancer mortality by 283,000 deaths among men and 87,000 deaths among women. This figure also indicates that a reduction of 372,000 lung cancer deaths among men and 78,000 lung cancer deaths among women, as was expected in the HFA target, would be reached if the percentage of smokers was decreased by around 45% among men and around 30% among women in each EU member state.
DISCUSSION
These results showed that the WHO's Health for All target on smoking cessation would give an expected total mortality reduction of 2.5% (around 1.1 million deaths) among men and 0.8% (almost 350,000 deaths) among women in the European Union, over the period 1994-2015. These and the expected cause-specific mortality declines in the HFA target were about 40-50% and 30% of the expected declines in the maximum target, among men and women respectively. The largest impact of the HFA target would be reached for lung cancer mortality. A comparable reduction in lung cancer mortality would be reached with a decrease in smoking prevalence in each EU member state of around 45% among men and 30% among women.
In public health modelling, Markov multi-state models are often used to model diseases or to estimate the effect of specific interventions on public health. 5, 8, 9 However, these models are a simplified reflection of real life and several assumptions were inevitable in these analyses. For instance, it was assumed that the groups of ex-and current smokers in the study were homogeneous groups with respect to mortality risk, whereas in reality, the relative risk for smoking-related mortality increases with increasing amount and duration of smoking and decreases with the duration of abstinence. However, since average group estimates of the relative risks for ex-and current smoking were used, it is expected that the differences in risk within ex-and current smokers will be partly averaged out in the analyses. There are several reasons why we were not able to incorporate the heterogeneity of smokers and ex-smokers into the model. First, information on the duration of smoking in EU member states was not available. Second, the time span over which risk increases after taking up smoking or decreases after abstinence is unclear for some causes of death. 2 And third, published relative risk estimates by amount and duration of smoking for the specific smoking-related causes of death would have been derived from different sources and would therefore have been difficult to compare. Moreover, it was assumed that the reduction in smoking prevalence in all but the maximum target, was due to smoking cessation alone and not to a reduction in the number of people who start to smoke. This assumption was made to make these targets comprehensible, since it would have been arbitrary which part of the reduction was due to smoking cessation and which part to not starting. People who start smoking are mostly young people, who still experience a low mortality risk over the simulation period. Although preventing those people from smoking would have a much larger impact on the mortality rate in the long run, within the time span of the simulation, this would have less impact on the mortality rate than encouraging older smokers to quit. If we had reduced the smoking prevalence in the HFA target (to 20% in each country) by a combination of smoking cessation and a reduction in the number of people who start smoking, the mortality reduction would have been smaller. Additional analyses of the data indeed showed that, in the extreme case that no one starts smoking, the HFA target would result in a reduction of total mortality up to 2015 of 1.8% and 0.4% among men and women respectively. Finally, it was assumed that the situation in the base population remained constant during the simulation period and that the only factor that could change was the transition rates for smoking Figure 1 Estimated relative reduction (absolute reduction above bars, rounded to the nearest 100) in mortality from lung cancer, other smoking-related cancers, CHD, stroke, COPD and total mortality in the EU following smoking cessation in the HFA target, cumulated between 1994 and 2015, among men and women aged 15 and over behaviour, whereas in reality several other factors may have changed. For instance, smoking behaviour may change spontaneously in the future without any smoking cessation intervention. Furthermore, treatment for several smokingrelated diseases may improve in future years, which may reduce mortality rates. Therefore, and because simplifications are inevitable, results from public health modelling and thus from this study are uncertain and should be interpreted only as an indication of the magnitude of the effect. However, these results are comparable to the scarce estimates from other studies. For instance, the International Agency for Research on Cancer (IARC) projected cancer mortality in 2015. 10 Although estimated differently, in general, there was a less than 10% difference between the IARC data and our reference scenario, with the exception of oral cavity/pharynx, larynx, and lung cancer mortality. For these types of cancer, the difference was larger, up to around 25% for larynx cancer. Furthermore, in the maximum target, results showed that, after instant elimination of cigarette smoking, within 21 years the number of all deaths would have been reduced by 6.3% among men and 2.6% among females. Peto et al. 3 estimated that yearly 24% of all male deaths and 6% of all female deaths are attributable to cigarette smoking. In the light of these estimations, the present results may seem disappointing. However, for the simulation that all smokers and ex-smokers in the population would have been never smokers, as Peto simulated, the number of all deaths within the simulation period decreased by 20.5% among men and 6.5% among women, which is comparable to the results Peto estimated. The differences between Peto's estimates and the results estimated in our targets are due to the fact that, in reality, giving up smoking reduces, but not immediately eliminates mortality risk, due to the remaining elevated risk of ex-smokers. For some causes of death, smoking cessation may eliminate risk only in the long run, after several decades. The maximum benefits of the elimination of cigarette smoking on mortality can thus only be seen when all ex-smokers with an elevated mortality risk have died, leading to a population of never smokers. This is a long-lasting process, which in theory may take over half a century, but in reality will never happen. Obviously, our maximum target is purely theoretical, since it is not realistic that all smokers quit smoking and no individual starts smoking. However, results indicate that even in the more feasible HFA target, smoking cessation would lead to a substantial reduction in mortality. Specifically, it is estimated that the HFA target would lead to a reduction of almost 1.5 million deaths (1.6%) within about 20 years in the EU, which is slightly more than the male population of Ireland in 1994. Overall, among men and women, the expected reductions in mortality from several causes of death in the HFA target were still around 40-50% and 30% of the expected declines in the maximum target, respectively. Among both men and women, the beneficial impact of smoking cessation appeared to be largest on lung cancer mortality. This finding is due to the high risk of smokers to die from lung cancer and to the large difference in relative risk for lung cancer mortality between smokers and ex-smokers, which was less pronounced for other causes of death. The lung cancer mortality risk among smokers is 12 to 22 times higher than that of never smokers and giving up smoking more than halves this risk. 1 On the contrary, among men, the number of deaths from COPD increased following smoking cessation in our estimations. This may be explained by the small difference in relative risk between smokers and ex-smokers for COPD mortality. Giving up smoking reduced the relative risk for COPD mortality by only around 9%. 1 This reduction in COPD mortality following smoking cessation was apparently too small to counterbalance the increase in COPD mortality as a result of a higher number of people at risk due to the reduced total mortality. Among women, the difference in relative risk for COPD mortality between smokers and ex-smokers was large enough to counterbalance the effect of competing causes of death. The decreased mortality from smoking-related diseases due to smoking cessation has great impact on the allocation of health care costs. In the UK, it is estimated that the health care costs for smoking-related diseases were around 1400-1500 million pounds per year. 11 It is obvious that smoking cessation would reduce these costs dramatically. Since non-smokers live longer than smokers, 12,13 it is uncertain whether the lower costs for smoking-related diseases among non-smokers are balanced out by the higher costs for other diseases at older ages.
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However, from an ethical point of view, the beneficial public health impact of smoking cessation for such a large part of the population should be of far more importance than the economic effects.
In conclusion, these results indicate that, if the Health for All target of the WHO with respect to smoking cessation could be achieved, the expected total mortality from 1994 to 2015 would be reduced by about 1.6% among men and women in the European Union, with the reduction in lung cancer mortality being the most important. Although this target may be difficult to realize, these results emphasize the need for policymakers in each member state of the European Union to put effort into encouraging smokers to quit smoking.
